Rare focus Target expansion opportunities by engaging Recordati Rare Diseases as a partner for access to investigational or approved therapies for ultra-rare conditions, leveraging their specialized portfolio and patient-first approach.

Acquisition momentum Capitalize on their recent and ongoing portfolio growth from acquisitions such as Enjaymo and EUSA Pharma assets to position complementary products or pipeline candidates that fit their rare-disease strategy.

Global reach Leverage their international exposure and US-Canada focus to propose cross-border collaborations, co-promotion opportunities, or regional supply arrangements for orphan drugs and niche therapeutics.

Digital engagement Offer tailored digital marketing and analytics partnerships that align with their patient-centric mission, including digital education campaigns, physician engagement tools, and compliance-friendly social media presence.

Awareness platforms Propose joint awareness initiatives and patient advocacy campaigns around rare diseases (e.g., Cushing’s awareness) to increase disease visibility while exploring co-branded therapeutic education and access programs.